Comments on Strang et al. (2016): 'Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?'.
Comments on Strang et al. (2016): 'Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?'.
复制标题
对斯特朗等人的评论
DOI：
10.1111/add.13399
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Walley,AlexanderY
中科院分区：
文献类型：
--
作者：
Doe-Simkins,Maya;Banta-Green,Caleb;Davis,CoreyS;Green,TraciC;Walley,AlexanderY
关于这篇文章的评论出现在”Coffin等人和Doe-Replikins等人的致瘾信：关于简易鼻用纳洛酮喷雾剂临床使用的“辩论”：作者的回应。“上瘾。2016年10月; 111（10）：1881-3。这是一个评论“临床提供简易鼻纳洛酮没有实验测试，没有监管批准：想象力的捷径或危险的旁路基本安全程序？“上瘾。2016年4月; 111（4）：574-82。
A comment on this article appears in" Letters to Addiction from Coffin et al. and Doe-Simpkins et al. re:'For Debate'on clinical use of improvised nasal naloxone sprays: authors' response." Addiction. 2016 Oct; 111 (10): 1881-3. This is a comment on" Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?" Addiction. 2016 Apr; 111 (4): 574-82.